Etrumadenant for Non-Small Cell Lung Cancer

Washington University School of Medicine, Saint Louis, MO
Non-Small Cell Lung Cancer+2 More ConditionsEtrumadenant - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the efficacy of a triple combination therapy for lung cancer patients who have previously been treated with other immunotherapy.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Non-Small Cell Carcinoma

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Through completion of follow-up (estimated to be 5 years)

Month 10
Number of study treatment related adverse events
Month 9
Number of discontinuations due to treatment-related adverse events
Year 5
Overall survival (OS)
Progression-free survival (PFS)
Month 9
Disease control rate (DCR)
Duration of response (DoR)
Objective response rate (ORR)

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Cohort A: Zimberelimab + Domvanalimab + Etrumadenant
1 of 2
Cohort B: Zimberelimab + Domvanalimab + Etrumadenant
1 of 2

Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Etrumadenant · No Placebo Group · Phase 2

Cohort A: Zimberelimab + Domvanalimab + EtrumadenantExperimental Group · 3 Interventions: Etrumadenant, Zimberelimab, Domvanalimab · Intervention Types: Drug, Drug, Drug
Cohort B: Zimberelimab + Domvanalimab + EtrumadenantExperimental Group · 3 Interventions: Etrumadenant, Zimberelimab, Domvanalimab · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Etrumadenant
2018
Completed Phase 1
~130
Zimberelimab
2018
Completed Phase 1
~50

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through completion of follow-up (estimated to be 5 years)

Who is running the clinical trial?

Arcus Biosciences, Inc.Industry Sponsor
33 Previous Clinical Trials
6,106 Total Patients Enrolled
Washington University School of MedicineLead Sponsor
1,846 Previous Clinical Trials
2,280,543 Total Patients Enrolled
Daniel Morgensztern, M.D.Principal InvestigatorWashington University School of Medicine
7 Previous Clinical Trials
92 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have brain tumors that have spread from another part of your body, but they are not causing immediate problems.
You can participate in the study even if you have cancer that has spread to your brain or meninges, as long as you meet certain conditions.

Frequently Asked Questions

How many participants have enrolled in this experiment thus far?

"Affirmative. Clinicaltrials.gov records demonstrate that this clinical trial, which was first introduced on August 4th 2021 is presently recruiting participants. The study seeks to enlist thirty people from a single medical centre." - Anonymous Online Contributor

Unverified Answer

Are individuals being enrolled in this trial presently?

"Affirmative. Research hosted on clinicaltrials.gov reveals that this investigation, which was initially published on August 4th 2021, is still accepting participants. Approximately 30 individuals are needed to be sourced from 1 location." - Anonymous Online Contributor

Unverified Answer

To what extent could Zimberelimab be detrimental to patients?

"Considering the drug is in a Phase 2 trial, with some evidence of safety but no proof of efficacy yet, our team at Power rated Zimberelimab's safety as a 2 on their rating scale." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.